The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations
Open accessAbstract
Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2), are present in most gliomas and secondary glioblastomas, but are rare in other neoplasms. IDH1/2 mutations are heterozygous, and affect a single arginine residue. Recently, IDH1 mutations were identified in 8% of acute myelogenous leukemia (AML) patients. A glioma study revealed that IDH1 mutations cause a gain-of-function, resulting in the production and accumulation of 2-hydroxyglutarate (2-HG). Genotyping of 145 AML biopsies identified 11 IDH1 R132 mutant samples. Liquid chromatography-mass spectrometry metabolite screening revealed increased 2-HG levels in IDH1 R132 mutant cells and sera, and uncovered two IDH2 R172K mutations. IDH1/2 mutations were associated with normal karyotypes. Recombinant IDH1 R132C and IDH2 R172K proteins catalyze the novel nicotinamide adenine dinucleotide phosphate (NADPH)–dependent reduction of α-ketoglutarate (α-KG) to 2-HG. The IDH1 R132C mutation commonly found in AML reduces the affinity for isocitrate, and increases the affinity for NADPH and α-KG. This prevents the oxidative decarboxylation of isocitrate to α-KG, and facilitates the conversion of α-KG to 2-HG. IDH1/2 mutations confer an enzymatic gain of function that dramatically increases 2-HG in AML. This provides an explanation for the heterozygous acquisition of these mutations during tumorigenesis. 2-HG is a tractable metabolic biomarker of mutant IDH1/2 enzyme activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The high concentrations of R-2HG (more than 10 mM) that have been observed in malignant brain tumours and leukaemias (Dang et al, 2009;Gross et al, 2010;Ward et al, 2010), might be sufficient to inhibit even the less-susceptible 2OG oxygenases.”
From The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases (2011) · cites this paper as Gross et al, 2010
In the citing paper
“However, they also cause a gain of function comprising catalysis of 2OG to the R-enantiomer of 2-hydroxyglutarate (R-2HG; Dang et al, 2009;Gross et al, 2010;Ward et al, 2010).”
From The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases (2011) · cites this paper as Gross et al, 2010
In the citing paper
“Tumor-associated IDH mutations unmask a latent ability of these enzymes to produce the R enantiomer of 2-hydroxyglutarate, which accumulates to low millimolar levels in IDH mutant tumors (Dang et al., 2009; Gross et al., 2010; Ward et al., 2010).”
From Influence of Metabolism on Epigenetics and Disease (2013) · cites this paper as Gross et al., 2010
In the citing paper
“AML samples with low to undetectable 2HG were subsequently sequenced and determined to be IDH1 and IDH2 wild-type”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Gross et al., 2010
In the citing paper
“several samples with elevated 2HG were found to have neomorphic mutations at either IDH1 R132 or IDH2 R172 (Gross et al., 2010)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Gross et al., 2010
In the citing paper
“Enzymatic assays and measurement of 2HG levels in primary AML samples confirmed that these IDH2 R172 mutations result in 2HG elevation (Gross et al., 2010; Ward et al., 2010).”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Gross et al., 2010
In the citing paper
“serum 2HG levels have successfully correlated with IDH1 R132 mutations in AML”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Gross et al., 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citationRecurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Hartmann, C. J., Meyer, J., Balß, J., Capper, D., Mueller, W. C., Christians, A., Felsberg, J., Wolter, M., Mawrin, C., Wick, W., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0561-9 · Cited by 1,163
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119
Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas
Sanson, M., Marie, Y., Paris, S., Idbaïh, A., Laffaire, J., Ducray, F., Hallani, S. E., Boisselier, B., Mokhtari, K., Hoang‐Xuan, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9832 · Cited by 1,049
Analysis of the IDH1 codon 132 mutation in brain tumors
Balss, J., Meyer, J., Mueller, W., Korshunov, A., Hartmann, C., & von Deimling, A. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0455-2 · Cited by 1,036
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas
Watanabe, T., Nobusawa, S., Kleihues, P., & Ohgaki, H. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080958 · Cited by 1,027
Nishihara, K., Kanemori, M., Kitagawa, M., Yanagi, H., & Yura, T. (1998) · Applied and Environmental Microbiology · doi:10.1128/aem.64.5.1694-1699.1998 · Cited by 440
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 744
Impact of MYC in regulation of tumor cell metabolism
Wahlström, T., & Arsenian‐Henriksson, M. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.07.004 · Cited by 176
Zebrafish and Medaka: new model organisms for modern biomedical research
Lin, C., Chiang, C.-Y., & Tsai, H. (2016) · Journal of Biomedical Science · doi:10.1186/s12929-016-0236-5 · Cited by 180
The Next Generation of Glioma Biomarkers: MGMT Methylation, BRAF Fusions and IDH1 Mutations
von Deimling, A., Korshunov, A., & Hartmann, C. J. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00454.x · Cited by 178
Tefferi, A., Jimma, T., Sulai, N. H., Lasho, T. L., Finke, C. M., Knudson, R. A., McClure, R. F., & Pardanani, A. D. (2011) · Leukemia · doi:10.1038/leu.2011.253 · Cited by 179
Tap, W. D., Villalobos, V. M., Cote, G. M., Burris, H., Janku, F., Mir, O., Beeram, M., Wagner, A. J., Jiang, L., Wu, B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02492 · Cited by 165
Metabolic remodelling during early mouse embryo development
Zhao, J., Yao, K., Yu, H., Zhang, L., Xu, Y., Chen, L., Sun, Z., Zhu, Y., Zhang, C., Qian, Y., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00464-x · Cited by 167
What do we know about IDH1/2 mutations so far, and how do we use it?
Horbinski, C. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1106-9 · Cited by 169
Understanding the central role of citrate in the metabolism of cancer cells
Icard, P., Poulain, L., & Lincet, H. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.10.007 · Cited by 167
Targeting cancer metabolism – aiming at a tumour's sweet-spot
Jones, N. P., & Schulze, A. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.017 · Cited by 164
Caravella, J. A., Lin, J., Diebold, R. B., Campbell, A.-M., Ericsson, A. M., Gustafson, G. R., Wang, Z., Castro, J., Clarke, A., Gotur, D., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01423 · Cited by 162
Li, S., Chou, A. P., Chen, W., Chen, R., Deng, Y., PHILLIPS, H. S., Selfridge, J. M., Zurayk, M., Lou, J. J., Everson, R. G., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos261 · Cited by 158
Glutamate and α-ketoglutarate: key players in glioma metabolism
Maus, A., & Peters, G. J. (2016) · Amino Acids · doi:10.1007/s00726-016-2342-9 · Cited by 162
Emadi, A., Jun, S. A., Tsukamoto, T., Fathi, A. T., Minden, M. D., & Dang, C. V. (2013) · Experimental Hematology · doi:10.1016/j.exphem.2013.12.001 · Cited by 167
Self-citationSong, Y., Wu, F., & Wu, J. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0279-9 · Cited by 154
Makishima, H., Jankowska, A. M., McDevitt, M. A., O’Keefe, C. L., Dujardin, S., Cazzolli, H., Przychodzen, B. P., Prince, C. J., Nicoll, J. M., Harish, S., et al. (2011) · Blood · doi:10.1182/blood-2010-06-292433 · Cited by 155
Inborn and acquired metabolic defects in cancer
Frezza, C., Pollard, P. J., & Gottlieb, E. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0728-4 · Cited by 147
Patnaik, M. M., Hanson, C. A., Hodnefield, J. M., Lasho, T. L., Finke, C. M., Knudson, R. A., Ketterling, R. P., Pardanani, A. D., & Tefferi, A. (2011) · Leukemia · doi:10.1038/leu.2011.298 · Cited by 147
Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China
Wang, J.-H., Chen, W., Li, J., Wu, S., Chen, T., Zhu, Y., Zhang, W., Li, Y., Qiu, Y.-P., Zhao, A.-H., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1315558110 · Cited by 146
Craddock, C., Quek, L. S., Goardon, N., Freeman, S. D., Siddique, S., Raghavan, M., Aztberger, A., Schuh, A., Grimwade, D. J., Ivey, A., et al. (2012) · Leukemia · doi:10.1038/leu.2012.312 · Cited by 147
Update on molecular findings, management and outcome in low-grade gliomas
Bourne, T. D., & Schiff, D. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.159 · Cited by 146
IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo
Bralten, L. B. C., Kloosterhof, N. K., Balvers, R. K., Sacchetti, A., Lapre, L., Lamfers, M. L. M., Leenstra, S., de Jonge, H. R., Kros, J. M., Jansen, E. E. W., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22390 · Cited by 148
Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling
Gagné, L. M., Boulay, K., Topisirović, I., Huot, M., & Mallette, F. A. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.06.002 · Cited by 143
de Botton, S., Fenaux, P., Yee, K. W. L., Récher, C., Wei, A. H., Montesinos, P., Taussig, D. C., Pigneux, A., Braun, T., Curti, A., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009411 · Cited by 140
DNA methylation as a transcriptional regulator of the immune system
Morales‐Nebreda, L., McLafferty, F. S., & Singer, B. D. (2018) · Translational research · doi:10.1016/j.trsl.2018.08.001 · Cited by 141
Borger, D. R., Goyal, L., Yau, T., Poon, R. T., Ancukiewicz, M., Deshpande, V., Christiani, D. C., Liebman, H. M., Yang, H., Kim, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2649 · Cited by 138
Self-citationMetabolomic signatures of aggressive prostate cancer
McDunn, J. E., Li, Z., Adam, K., Neri, B. P., Wolfert, R. L., Milburn, M. V., Lotan, Y., & Wheeler, T. M. (2013) · The Prostate · doi:10.1002/pros.22704 · Cited by 138
Chen, J.-Y., Li, C., Kuo, C.-C., Tsai, K. K., Hou, M., & Hung, W.-C. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0410-1 · Cited by 145
Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date
Bastien, J., McNeill, K. A., & Fine, H. A. (2014) · Cancer · doi:10.1002/cncr.28968 · Cited by 146
Banh, R. S., Iorio, C., Marcotte, R., Xu, Y., Cojocari, D., Rahman, A. M. A., Pawling, J., Zhang, W., Sinha, A., Rose, C. M., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3376 · Cited by 136
Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia
Chan, S. M., & Majeti, R. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1407-8 · Cited by 142
Metabolic alterations in cancer cells and therapeutic implications
Hammoudi, N., Ahmed, K. B. R., Garcı́a-Prieto, C., & Huang, P. (2011) · 癌症：英文版 · doi:10.5732/cjc.011.10267 · Cited by 137
IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma
Zhang, C., Moore, L. M., Li, X., Yung, W. K. A., & Zhang, W. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not087 · Cited by 136
IDH mutations in acute myeloid leukemia
Rakheja, D., Konoplev, S. N., Medeiros, L. J., & Chen, W. (2012) · Human Pathology · doi:10.1016/j.humpath.2012.05.003 · Cited by 135
Scotland, S., Saland, E., Skuli, N., de Toni, F., Boutzen, H., Micklow, E., Sénégas, I., Peyraud, R., Peyriga, L., Théodoro, F., et al. (2013) · Leukemia · doi:10.1038/leu.2013.107 · Cited by 149
2-Hydroxyglutarate in Cancer Cells
Ježek, P. (2020) · Antioxidants & Redox Signaling · doi:10.1089/ars.2019.7902 · Cited by 130
Mutant IDH1 Confers an in Vivo Growth in a Melanoma Cell Line with BRAF Mutation
Shibata, T., Kokubu, A., Miyamoto, M., Sasajima, Y., & Yamazaki, N. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.12.011 · Cited by 131
Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight
Al‐Khallaf, H. (2017) · Cell & Bioscience · doi:10.1186/s13578-017-0165-3 · Cited by 133
Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML
Wei, A. H., & Tiong, I. S. (2017) · Blood · doi:10.1182/blood-2017-08-784066 · Cited by 129
Leverson, J. D., Sampath, D., Souers, A. J., Rosenberg, S. H., Fairbrother, W. J., Amiot, M., Konopleva, M. Y., & Letai, A. G. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0797 · Cited by 126
Böttcher, M., Renner, K., Berger, R., Mentz, K., Thomas, S., Cardenas-Conejo, Z. E., Dettmer, K., Oefner, P. J., Mackensen, A., Kreutz, M., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1445454 · Cited by 124
Icard, P., & Lincet, H. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.07.001 · Cited by 133
Fathi, A. T., Sadrzadeh, H., Borger, D. R., Ballen, K. K., Amrein, P. C., Attar, E. C., Foster, J., Burke, M. E., Lopez, H. U., Matulis, C. R., et al. (2012) · Blood · doi:10.1182/blood-2012-06-438267 · Cited by 125
Self-citationAlterations of metabolic genes and metabolites in cancer
Oermann, E. K., Wu, J., Guan, K., & Xiong, Y. (2012) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2012.01.013 · Cited by 125
Chaturvedi, A., Herbst, L., Pusch, S., Klett, L. C., Goparaju, R., Stichel, D., Kaulfuß, S., Panknin, O., Zimmermann, K. C., Toschi, L., et al. (2017) · Leukemia · doi:10.1038/leu.2017.46 · Cited by 125
Watts, J. M., Baer, M. R., Yang, J., Prébet, T., Lee, S., Schiller, G. J., Dinner, S. N., Pigneux, A., Montesinos, P., Wang, E. S., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00292-7 · Cited by 122
Janin, M., Mylonas, E., Saada, V., Micol, J., Renneville, A., Quivoron, C., Koscielny, S., Scourzic, L., Forget, S., Pautas, C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.2047 · Cited by 131
Grassian, A. R., Lin, F., Barrett, R., Liu, Y., Jiang, W., Korpal, M., Astley, H. M., Gitterman, D. P., Henley, T., Howes, R., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.417832 · Cited by 122
Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL
Karpel‐Massler, G., Ishida, C. T., Bianchetti, E., Zhang, Y., Shu, C., Tsujiuchi, T., Banu, M. A., Garcia, F., Roth, K. A., Bruce, J. N., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00984-9 · Cited by 121
Genetic alterations in Krebs cycle and its impact on cancer pathogenesis
Sajnani, K., Islam, F., Smith, R. A., Gopalan, V., & Lam, A. K.-Y. (2017) · Biochimie · doi:10.1016/j.biochi.2017.02.008 · Cited by 121
Zhu, J., Xiong, Y., Zhang, Y., Wen, J., Cai, N., Cheng, K., Liang, H., & Zhang, W. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/8810785 · Cited by 116
Traina, F., Visconte, V., Jankowska, A. M., Makishima, H., O’Keefe, C. L., Elson, P. J., Han, Y., Hsieh, F. H., Sekeres, M. A., Mali, R. S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043090 · Cited by 122
Chotirat, S., Thongnoppakhun, W., Promsuwicha, O., Boonthimat, C., & Auewarakul, C. U. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-5 · Cited by 116
5-hydroxymethylcytosine in cancer: significance in diagnosis and therapy
Vasanthakumar, A., & Godley, L. A. (2015) · Cancer Genetics · doi:10.1016/j.cancergen.2015.02.009 · Cited by 116
Jin, G., Reitman, Z. J., Spasojevic, I., Batinic-Haberle, I., Yang, J., Schmidt-Kittler, O., Bigner, D. D., & Yan, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016812 · Cited by 112
Oxidative stress and hypoxia in normal and leukemic stem cells
Testa, U., Labbaye, C., Castelli, G., & Pelosi, E. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.04.012 · Cited by 118
TET2 as an epigenetic master regulator for normal and malignant hematopoiesis
Nakajima, H., & Kunimoto, H. (2014) · Cancer Science · doi:10.1111/cas.12484 · Cited by 117
Wu, H., Ying, M., & Hu, X. (2016) · Oncotarget · doi:10.18632/oncotarget.9746 · Cited by 114
Targeting Cancer Metabolism - Revisiting the Warburg Effects
Tran, Q., Lee, H., Park, J., Kim, S., & Park, J. (2016) · Toxicological Research · doi:10.5487/tr.2016.32.3.177 · Cited by 116
Colvin, H. S., Nishida, N., Konno, M., Haraguchi, N., Takahashi, H., Nishimura, J., Hata, T., Kawamoto, K., Asai, A., Tsunekuni, K., et al. (2016) · Scientific Reports · doi:10.1038/srep36289 · Cited by 111
Li, L., Paz, A. C., Wilky, B. A., Johnson, B. A., Galoian, K. A., Rosenberg, A. E., Hu, G., Tinoco, G., Bodamer, O. A., & Trent, J. C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133813 · Cited by 107
The Role of Mitochondrial NADPH-Dependent Isocitrate Dehydrogenase in Cancer Cells
Smolková, K., & Ježek, P. (2012) · International Journal of Cell Biology · doi:10.1155/2012/273947 · Cited by 114
Targeting glucose metabolism in patients with cancer
Elf, S., & Chen, J. (2013) · Cancer · doi:10.1002/cncr.28501 · Cited by 108
Molecular Distinction of Chondrosarcoma From Chondroblastic Osteosarcoma Through IDH1/2 Mutations
Kerr, D. A., Lopez, H. U., Deshpande, V., Hornicek, F. J., Duan, Z., Zhang, Y., Rosenberg, A. E., Borger, D. R., & Nielsen, G. P. (2013) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31827ab703 · Cited by 105
van Gils, N., Denkers, F., & Smit, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.659253 · Cited by 108
Serum metabolomics analysis for early detection of colorectal cancer
Uchiyama, K., Yagi, N., Mizushima, K., Higashimura, Y., Hirai, Y., Okayama, T., Yoshida, N., Katada, K., Kamada, K., Handa, O., et al. (2016) · Journal of Gastroenterology · doi:10.1007/s00535-016-1261-6 · Cited by 105
Patnaik, M. M., Lasho, T. L., Finke, C. M., Gangat, N., Caramazza, D., Holtan, S. G., Pardanani, A. D., Knudson, R. A., Ketterling, R. P., Chen, D., et al. (2010) · Leukemia · doi:10.1038/leu.2010.105 · Cited by 102
Taming the dragon: genomic biomarkers to individualize the treatment of cancer
Majewski, I. J., & Bernards, R. (2011) · Nature Medicine · doi:10.1038/nm.2311 · Cited by 101
Structural analysis of oncogenic mutation of isocitrate dehydrogenase 1
Rajendran, V. (2016) · Molecular BioSystems · doi:10.1039/c6mb00182c · Cited by 98
Hu, X., Chao, M., & Wu, H. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2016.47 · Cited by 102
The multifaceted contribution of α-ketoglutarate to tumor progression: An opportunity to exploit?
Abla, H., Sollazzo, M., Gasparre, G., Iommarini, L., & Porcelli, A. M. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.031 · Cited by 99
Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH Mutations in Glioblastoma
Krell, D., Assoku, M., Galloway, M., Mulholland, P. J., Tomlinson, I. P. M., & Bardella, C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019868 · Cited by 94
Fathi, A. T., & Abdel-Wahab, O. I. (2011) · Advances in Hematology · doi:10.1155/2012/469592 · Cited by 95
Davis, M. I., Größ, S., Shen, M., Straley, K. S., Pragani, R., Lea, W., Popovici-Müller, J. V., DeLaBarre, B., Artin, E., Thorne, N., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.511030 · Cited by 93
Self-citationIDH1 and IDH2 mutations in pediatric acute leukemia
Andersson, A., Miller, D. W., Lynch, J. A., Lemoff, A. S., Cai, Z., Pounds, S. B., Radtke, I., Yan, B., Schuetz, J. D., Rubnitz, J. E., et al. (2011) · Leukemia · doi:10.1038/leu.2011.133 · Cited by 96
MicroRNA-183 upregulates HIF-1α by targeting isocitrate dehydrogenase 2 (IDH2) in glioma cells
Tanaka, H., Sasayama, T., Tanaka, K., Nakamizo, S., Nishihara, M., Mizukawa, K., Kohta, M., Koyama, J., Miyake, S., Taniguchi, M., et al. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-1027-9 · Cited by 96
Epigenetics in Cancer: A Hematological Perspective
Stahl, M. F., Kohrman, N., Gore, S. D., Kim, T. K., Zeidan, A. M., & Prébet, T. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006193 · Cited by 92
Isocitrate dehydrogenase mutations in gliomas
Guo, C., Pirozzi, C. J., Lopez, G. Y., & Yan, H. (2011) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32834cd415 · Cited by 93
Drabovich, A. P., Pavlou, M. P., Dimitromanolakis, A., & Diamandis, E. P. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.015214 · Cited by 90
Pusch, S., Schweizer, L., Beck, A.-C., Lehmler, J.-M., Weißert, S., Balß, J., Miller, A. K., & von Deimling, A. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-19 · Cited by 93
Alam, M. M., Lal, S., FitzGerald, K. E., & Li, Z. (2016) · Clinical and Translational Medicine · doi:10.1186/s40169-016-0082-9 · Cited by 92
D2HGDH regulates alpha-ketoglutarate levels and dioxygenase function by modulating IDH2
Lin, A., Abbas, S., Kim, S., Ortega, M. M., Bouamar, H., Escobedo, Y. A., Varadarajan, P., Qin, Y., Sudderth, J., Schulz, E., et al. (2015) · Nature Communications · doi:10.1038/ncomms8768 · Cited by 88
Readers of DNA methylation, the MBD family as potential therapeutic targets
Ginder, G. D., & Williams, D. C. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.11.002 · Cited by 92
Cheng, Q.-Y., Xiong, J., Huang, W., Ma, Q., Ci, W., Feng, Y., & Yuan, B. (2015) · Scientific Reports · doi:10.1038/srep15217 · Cited by 84
Capper, D., Simon, M., Langhans, C., Okun, J. G., Tonn, J. C., Weller, M., von Deimling, A., Hartmann, C. J., & for the German Glioma Network (2011) · International Journal of Cancer · doi:10.1002/ijc.26425 · Cited by 83
Interactions between epigenetics and metabolism in cancers
Yun, J., Johnson, J. L., Hanigan, C. L., & Locasale, J. W. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00163 · Cited by 82
Molenaar, R. J., Coelen, R. J. S., Khurshed, M., Roos, E., Caan, M. W. A., Linde, M. E. V., Kouwenhoven, M. C. M., Bramer, J. A. M., Bovée, J. V. M. G., Mathôt, R. A. A., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-014961 · Cited by 83
Novel IDH1-Targeted Glioma Therapies
Karpel‐Massler, G., Nguyen, T. T. T., Shang, E., & Siegelin, M. D. (2019) · CNS Drugs · doi:10.1007/s40263-019-00684-6 · Cited by 82
Suppression of T-cell responses by tumor metabolites
Singer, K., Gottfried, E., Kreutz, M. P., & Mackensen, A. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0967-1 · Cited by 84
Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas
Hemerly, J. P., Bastos, A. U., & Cerutti, J. M. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0473 · Cited by 84
Deneberg, S., Guardiola, P., Lennartsson, A., Qu, Y., Gaidzik, V., Blanchet, O., Karimi, M., Bengtzén, S., Nahi, H., Uggla, B., et al. (2011) · Blood · doi:10.1182/blood-2011-01-332353 · Cited by 84
Isocitrate Dehydrogenase 1 Analysis Differentiates Gangliogliomas from Infiltrative Gliomas
Horbinski, C., Kofler, J., Yeaney, G. A., Camelo-Piragua, S. I., Venneti, S., Louis, D. N., Perry, A., MURDOCH, G. H., & Nikiforova, M. N. (2011) · Brain Pathology · doi:10.1111/j.1750-3639.2011.00480.x · Cited by 80
Mutant IDH1 Enhances the Production of 2-Hydroxyglutarate Due to Its Kinetic Mechanism
Rendina, A. R., Pietrak, B., Smallwood, A. M., Zhao, H., Qi, H., Quinn, C. J., Adams, N. D., Concha, N. O., Duraiswami, C., Thrall, S. H., et al. (2013) · Biochemistry · doi:10.1021/bi400514k · Cited by 81
Chromatin modifiers and the promise of epigenetic therapy in acute leukemia
Greenblatt, S. M., & Nimer, S. D. (2014) · Leukemia · doi:10.1038/leu.2014.94 · Cited by 83
Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds
Wu, F., Jiang, H., Zheng, B., Kogiso, M., Yao, Y., Zhou, C., Li, X., & Song, Y. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00684 · Cited by 78
Mutations in the Isocitrate Dehydrogenase Genes IDH1 and IDH2 in Tumors
Schaap, F. G., French, P. J., & Bovée, J. V. M. G. (2012) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e31827b654d · Cited by 80
Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase
Zheng, B., Yao, Y., Liu, Z., Deng, L., Anglin, J. L., Jiang, H., Prasad, B. V. V., & Song, Y. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400036z · Cited by 76
Fathi, A. T., Sadrzadeh, H., Comander, A. H., Higgins, M. J., Bardia, A., Perry, A. M., Burke, M. E., Silver, R. M., Matulis, C. R., Straley, K. S., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0417 · Cited by 77
Self-citationMetabolism and the leukemic stem cell
Abdel-Wahab, O. I., & Levine, R. L. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20100523 · Cited by 81
Isocitrate dehydrogenase mutations in leukemia
McKenney, A. S., & Levine, R. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67266 · Cited by 78
IDH1 and IDH2: Not Your Typical Oncogenes
Reitman, Z. J., Parsons, D. W., & Yan, H. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.02.024 · Cited by 75
Metadata
- Authors
- Gross, S., Cairns, R. A., Minden, M. D., Driggers, E. M., Bittinger, M. A., Jang, H. G., Sasaki, M., Jin, S., Schenkein, D. P., Su, S. M., Dang, L., Fantin, V. R., & Mak, T. W.
- Affiliations
- Agios Pharmaceuticals Incorporated, Cambridge, MA 02139 1
- University Health Network (CA)
- Agios Pharmaceuticals (United States) (US)
- Corresponding author
- Fantin, Valeria R.
- Mak, Tak W.
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2010-02-08
- Volume
- 207
- Issue
- 2
- Pages
- 339-344
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC2822606
- OpenAlex
- W2159731673
- Cited by
- 736
- References
- 23
- Citations by year
- 2026: 10 · 2025: 19 · 2024: 34 · 2023: 35 · 2022: 29 · 2021: 55 · 2020: 40 · 2019: 36 · 2018: 45 · 2017: 51 · 2016: 61 · 2015: 44 · 2014: 49 · 2013: 61 · 2012: 61
- FWCI
- 45.76
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- Leukemia and Lymphoma Society
- Agios Pharmaceuticals
- Terry Fox Foundation
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- 2-hydroxyglutarate, IDH mutation, acute myeloid leukemia, alpha-ketoglutarate, NADPH-dependent reduction, gain-of-function mutations, cancer metabolism, metabolic biomarkers
- MeSH terms
- Catalysis, Glutarates, Humans, Isocitrate Dehydrogenase, Ketoglutaric Acids, Mutation, NADP, Recombinant Proteins, Leukemia, Myeloid, Acute
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
